Scientific expertise shaping the future of multispecific therapeutics

Barbara joined Numab in 2025. She brings more than 20 years of global biopharmaceutical leadership experience across business development, commercialization, corporate strategy and company building. Prior to joining Numab, Barbara held executive leadership roles at Asceneuron, Vifor Pharma Group, Amgen, Onyx Pharmaceuticals and Exelixis and co-founded Stepstone Pharma. She has contributed to major financing and strategic transactions, including leading Asceneuron's $100 million Series C financing and supporting Vifor Pharma’s $11.7 billion acquisition by CSL. Barbara serves as a Non-Executive Director at Bellevue Group and medmix Group AG and holds bachelor's and master's degrees in Business Administration from the University of St. Gallen, Switzerland.

Raj joined Numab in 2026, bringing nearly 40 years of experience across oncology, immunology and drug development in industry and academia, including senior roles at AstraZeneca, Celgene, The Institute of Cancer Research in London and multiple biotechnology companies. Raj has a proven track record in drug discovery, translational science and clinical development, having contributed to 40 IND submissions, seven NDAs and 19 published patents. He is an experienced cancer physician and scientist and has advised and served on the boards of several biotechnology campanies. Raj holds an MBBS with Honours and a PhD from the University of London and is a Fellow of the Royal College of Physicians, the Royal College of Pathologists and the Royal Society of Biologists.

James joined Numab in 2021 and currently serves as Chief Legal Officer, General Counsel and Board Secretary. He brings more than 20 years of experience advising leading healthcare, biotechnology and investment organizations. Prior to joining Numab, James served as General Counsel for Waypoint Capital and its healthcare investment fund, Gurnet Point Capital, and held board positions with several life sciences companies. Earlier, he held senior leadership roles at Serono and Merck KGaA, supporting research and development, venture investments, business development and corporate transactions. James holds a degree in Political Science from the University at Albany and a Juris Doctor from New York University School of Law.

Stefan joined Numab in 2015 and has played a pivotal role in building and scaling the company’s technology platform and development capabilities. As Chief Technology Officer, Stefan leads Numab’s protein engineering as well as all Chemistry, Manufacturing and Controls (CMC) activities, overseeing the company’s development and manufacturing capabilities. Stefan has been instrumental in progressing multiple pipeline programs into clinical development, including NM26, which was acquired by Johnson & Johnson in 2024. Before joining Numab, Stefan held roles in pharmaceutical development at CSL Behring, where the focus was on process development and manufacturing optimization. Stefan holds a degree in Biochemistry from ETH Zurich and a PhD in Structural Biology and Biochemistry from the University of Zurich.

Andrew joined Numab in 2026, bringing more than 30 years of biologics development experience across immunology, inflammation and oncology. Throughout his career, Andrew has guided innovative therapies from research through clinical development and late-stage development. Prior to joining Numab, he held senior leadership roles at MoonLake Immunotherapeutics, Akamis Bio, AstraZeneca and Amgen. Andrew holds a degree in Biological Sciences from the University of Birmingham, United Kingdom.

Alain joined Numab in 2026 heading People & Culture. He brings more than 20 years of experience in organizational development, talent management and culture transformation across healthcare, financial services and technology-driven industries. Before joining Numab, he held leadership roles at the University Hospital Zurich, Sonova, UBS Wealth Management and Korn Ferry,. He holds a master's degree in Social Anthropology, Modern History and Political Science from the University of Zurich and a Certificate of Advanced Studies in Mentoring & Coaching from Sheffield Hallam University.

Tea has been with Numab since 2011 and helped establish the company's antibody discovery platform. Prior to Numab, Tea served as Head of PK & PD at ESBATech, where she led the pharmacokinetic and pharmacodynamic characterization of antibody fragments and supported preclinical development programs in ophthalmology and immuno-oncology, contributing to the discovery and preclinical development of commercialized assets. Tea holds a degree in Molecular Biology and Immunology and a PhD in Molecular Biology from the University of Zurich.

Uyum joined Numab in 2025 and brings extensive experience in business development and portfolio strategy across the biopharmaceutical and healthcare industries. Her track record includes strategic partnerships, transactions, post-merger integration and asset value creation spanning early-stage research through commercialization. Before joining Numab, she held senior roles at Asceneuron, CSL Vifor, Vifor Pharma and Baxter International, Uyum holds a degree in Chemistry from Bogazici University and a master’s degree in Management, Technology & Economics from ETH Zurich.

Carlo Incerti was appointed to the Numab Board of Directors in June 2021. He currently holds the position of Operating Partner at Forbion. A medical doctor by training, Carlo Incerti brings over three decades of experience in the biopharmaceutical industry. He most recently held the position of Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme. Before his time at Sanofi and Genzyme, Carlo was a founding shareholder, Board member, and Chief Executive officer at Biofil S.r.l., a start-up active in the development, manufacturing, and commercialization of systems for leukocyte depletion of blood and derivatives, which was acquired by Fresenius Kabi of Germany in 1993. Prior to joining the industry, Carlo was an Associate Professor of Endocrinology at the University of Modena, with a main research focus on thyroid diseases and sex hormones. Carlo currently also serves on the board of Azafaros B.V. (Chairman), EryDel S.p.A (Chairman), Inversago Pharma (Chairman), VectorY (Chairman), and is a Founding Member and on the Consortium Assembly of IRDiRC, the International Rare Diseases Research Consortium.

Michael Bauer was appointed to the Numab Board of Directors in June 2021. He currently holds the position as Venture Partner at Novo Holdings. From 2006-2020, Michael was employed at Genmab in various positions with increasing responsibility, starting in Project Management taking daratumumab / DARZALEX® into clinical development. Between 2010-2018 he led Clinical Development and was part of the senior leadership team that repositioned and rebuilt the company into a global cancer and antibody powerhouse. From 2018 he led R&D Operations preparing the company for filing of its first own product. Prior to Genmab, Michael worked as an Associate at BankInvest Biomedical Venture and as Licensing Associate in Scientific Licensing at Novo Nordisk, after having spent 7 years as Research Scientist at Novo Nordisk covering areas such as endocrinology, metabolic disease, cancer, and inflammation. Before joining the industry, Michael worked for 6 years at the Research Centre for Developmental Medicine & Biology at the University of Auckland, New Zealand, investigating causes and possible treatment modalities of intra-uterine growth restriction. Michael earned a Masters (Dipl. Ing. agr.) in Agricultural Science from the University of Stuttgart-Hohenheim, Germany, and a Ph.D. in Agricultural Science – summa cum laude – from the University of Göttingen, Germany. Michael currently has no additional board seats.

Matthias Fehr was appointed to the Numab Board of Directors in June 2021. He currently holds the position of Head of Private Equity at HBM Partners. Matthias has more than twenty years of experience in private and public equity investment management and research. He is a former senior sell-side analyst at Lombard Odier for the biotech and medical technology industries. Matthias is a former scientist at the Swiss Federal Institute of Technology and holds an MSc and Ph.D. in chemistry from ETH Zurich. He is also a Chartered Financial Analyst since 2002. Matthias currently also serves on the board of Swixx Biopharma.

Oliver was the Chief Business Officer and a co-founder of Numab. From 2004 until 2010, he was at ESBATech as Head of Alliance Management and responsible for intellectual property. After the acquisition by Alcon in September 2009, Oliver became a member of Alcon’s R&D Alliance Group, tasked with search, evaluation, negotiations and alliance management of collaborations, while remaining Head of Alliance Management at ESBATech, and a member of the ESBATech Management. Oliver studied Molecular Biology and Immunology at the University of Zurich and received his PhD in Biochemistry from the University of Basel in 2004.

David was the Chief Executive Officer and a co-founder of Numab. Prior to starting Numab, David was Head of Research & Development at ESBATech, where he conceived and implemented ESBATech’s antibody discovery platform. He was responsible for the discovery and preclinical development of brolucizumab/Beovu®, a best-in-class anti-VEGF fragment for the treatment of age-related macular edema, launched by Novartis. David holds an MSc in Molecular Biology and Neurosciences from the University of Zurich, and a PhD in Biochemistry from the Biocenter in Basel.